Actively Recruiting

Age: 15Years - 18Years
All Genders
ID07160153

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Led by University Hospital Pilsen · Updated on 2025-09-19

29

Participants Needed

1

Research Sites

34 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to assess how cognitive functions develop after achieving abstinence in adolescents diagnosed with cannabis dependence or harmful cannabis use. The study focuses on a group of young people aged 15 to 18 years, with abstinence confirmed through toxicological testing. The goal is to understand changes in brain function following cannabis abstinence during adolescence. Participants undergo neurocognitive assessments using a variety of tests, including the Trail Making Test, Auditory Verbal Learning Test, Stroop Test, Tower of London, and Continuous Performance Test-Identical Pairs. Urine toxicological assessments are used to confirm abstinence. The study observes cognitive performance changes over an 8-week period. During the study, participants will take these cognitive tests and provide urine samples to monitor abstinence. Researchers will measure changes in cognitive abilities such as attention, memory, and problem-solving. The main outcome is the change in performance on the Trail Making Test Part B after 8 weeks. Safety and adherence to abstinence are closely monitored throughout the study period, which lasts 8 weeks.

CONDITIONS

Brief Title

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Who Can Participate

Age: 15Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Not Eligible

You will not qualify if you...

  • Psychiatric comorbidity such as psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, except stabilized anxiety disorder.
  • Use of antipsychotics prescribed for psychosis.
  • Severe endocrine disorders including diabetes mellitus and thyroid dysfunction.
  • Severe cardiovascular disease.
  • Breaking abstinence between the first and second neuropsychological assessments.
  • Severe mental state worsening requiring changes in psychopharmacological treatment.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 8 weeks

Participants undergo neurocognitive testing and urine toxicological assessments to evaluate cognitive functions and confirm abstinence.

2 neurocognitive and toxicological assessment visits

Long-term Monitoring

Duration - Up to 8 weeks

Participants are observed to assess cognitive performance changes following cannabis abstinence.

Follow-up assessments may occur to monitor cognitive development

Trial Site Locations

Total: 1 location

1

University Hospital Pilsen

Pilsen, Czechia, Czechia, 30100

Actively Recruiting

Loading map...

Research Team

J

Jiri Podlipny, MD, Ph.D.

F

Frantisek Nekvapil, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Efficacy of a Digitalized Selective Prevention Program (App ...

Cannabis Dependence

Actively Recruiting

2 locations

A Randomized, Double-Blind, Placebo-Controlled Trial of Sema...

Cannabis Use Disorder

Actively Recruiting

1 location

A Double-blind, Placebo-controlled, Randomised, Acute, Repea...

Cognitive Assessment

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here